Sinopharm Group Co Ltd Class H (HK:1099)
:1099
Want to see HK:1099 full AI Analyst Report?
1099 Stock Chart & Stats
HK$20.28
-HK$0.15(-0.74%)
At close: 4:00 PM EST
HK$20.28
-HK$0.15(-0.74%)
Day’s Range― - ―
52-Week RangeHK$16.43 - HK$22.34
Previous CloseN/A
Volume3.49M
Average Volume (3M)4.67M
Market Cap
HK$52.43B
Enterprise ValueHK$92.65B
Total Cash (Recent Filing)HK$61.59B
Total Debt (Recent Filing)HK$108.63B
Price to Earnings (P/E)6.4
Beta0.76
Next Earnings
Aug 31, 2026EPS Estimate
1.26Next Dividend Ex-DateN/A
Dividend Yield3.75%
Share Statistics
EPS (TTM)2.29
Shares Outstanding1,341,810,800
10 Day Avg. Volume3,523,930
30 Day Avg. Volume4,674,378
Financial Highlights & Ratios
PEG Ratio5.74
Price to Book (P/B)0.65
Price to Sales (P/S)0.09
P/FCF Ratio4.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$22.83Price Target Upside12.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)2.43
Revenue Forecast (FY)HK$592.91B
Bulls Say, Bears Say
Bulls Say
Profit IncreaseNet profit for Sinopharm's Guoda pharmacy chain jumped 215.8% YoY.
Revenue GrowthRevenue from SPD (supply processing and distribution) and centrally procured contracts increased ~13% YoY.
Sales GrowthSame-store sales growth for Sinopharm's direct-to-patient pharmacies was >10% YoY, driven by innovative drugs.
Bears Say
Hospital Payment CyclesLengthening hospital payment cycles continue to weigh on the balance sheet with AR days increased 11 days YoY to 143 days.
Market EnvironmentRevenue decline was less severe than projected for the entire medtech segment, indicating a challenging market environment.
Operating Cash FlowOperating cash flow was a negative Rmb34.1bn in 1H25, versus a negative Rmb41.0bn in 1H24.
Sinopharm Group Co News
1099 FAQ
What was Sinopharm Group Co Ltd Class H’s price range in the past 12 months?
Sinopharm Group Co Ltd Class H lowest stock price was HK$16.43 and its highest was HK$22.34 in the past 12 months.
What is Sinopharm Group Co Ltd Class H’s market cap?
Sinopharm Group Co Ltd Class H’s market cap is HK$52.43B.
When is Sinopharm Group Co Ltd Class H’s upcoming earnings report date?
Sinopharm Group Co Ltd Class H’s upcoming earnings report date is Aug 31, 2026 which is in 79 days.
How were Sinopharm Group Co Ltd Class H’s earnings last quarter?
Sinopharm Group Co Ltd Class H released its earnings results on Apr 27, 2026. The company reported HK$0.518 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.518.
Is Sinopharm Group Co Ltd Class H overvalued?
According to Wall Street analysts Sinopharm Group Co Ltd Class H’s price is currently Undervalued.
Does Sinopharm Group Co Ltd Class H pay dividends?
Sinopharm Group Co Ltd Class H pays a Annually dividend of HK$0.888 which represents an annual dividend yield of 3.75%. See more information on Sinopharm Group Co Ltd Class H dividends here
What is Sinopharm Group Co Ltd Class H’s EPS estimate?
Sinopharm Group Co Ltd Class H’s EPS estimate is 1.26.
How many shares outstanding does Sinopharm Group Co Ltd Class H have?
Sinopharm Group Co Ltd Class H has 1,341,810,800 shares outstanding.
What happened to Sinopharm Group Co Ltd Class H’s price movement after its last earnings report?
Sinopharm Group Co Ltd Class H reported an EPS of HK$0.518 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.798%.
Which hedge fund is a major shareholder of Sinopharm Group Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:1099
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sinopharm Group Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.05%
12-Months-Change
Fundamentals
Return on Equity
8.70%
Trailing 12-Months
Asset Growth
3.79%
Trailing 12-Months
Company Description
Sinopharm Group Co Ltd Class H
Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of China's healthcare market, specializing in the wholesale and retail of pharmaceuticals, medical devices, and related health products. The company's business activities are organized across four main divisions. Its Pharmaceutical Distribution segment supplies pharmaceutical goods to a wide range of clients, including hospitals, fellow distributors, retail pharmacies, and clinics. This division additionally offers extensive distribution, logistics, and value-added support to both domestic and international manufacturers and suppliers in the pharmaceutical and healthcare sectors. The Medical Devices segment is solely focused on the distribution of various medical equipment. Through its Retail Pharmacy division, Sinopharm manages and franchises a vast chain of drug stores, with an impressive 10,259 locations as of December 31, 2021. The "Other Business" segment is involved in the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core areas, the company also engages in property rental and management. It further distributes specialized items such as medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products. Sinopharm provides a comprehensive array of services, including IT development, medicine and health consultations, investment services, import/export facilitation for goods and technology, various business and market information consulting, and the organization of conventions and exhibitions. Moreover, it oversees medical project investments, offers related consulting, and provides technological training. Notably, Sinopharm Group has established a strategic alliance with I-Mab to enhance its commercial capabilities and accelerate its market entry strategies. Founded in Shanghai, China, in 2003, Sinopharm Group Co. Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.
1099 Stock 12 Month Forecast
Average Price Target
HK$22.83
▲(12.55% Upside)
Technical Analysis
China Health Group
―
Shanghai Pharmaceuticals Holding Co
―
IVD Medical Holding Limited
―
Medlive Technology Co., Ltd.
―
Charmacy Pharmaceutical Co., Ltd. Class H
―
Options Prices
Currently, No data available
---